Database: Sculptra/New-Fill

nvcg1NVCG Commissie Wetenschap

Database: Sculptra/New-Fill

 

 

 

  1. Friedmann, D.P., S.G. Fabi, and M.P. Goldman, Combination of intense pulsed light, Sculptra, and Ultherapy for treatment of the aging face. J Cosmet Dermatol, 2014. 13(2): p. 109-18.
  2. Duracinsky, M., et al., Safety of poly-L-lactic acid (New-Fill(R)) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients. BMC Infect Dis, 2014. 14: p. 474.
  3. Alessio, R., et al., European expert recommendations on the use of injectable poly-L-lactic acid for facial rejuvenation. J Drugs Dermatol, 2014. 13(9): p. 1057-66.
  4. Schuller-Petrovic, S., et al., Early granulomatous foreign body reactions to a novel alginate dermal filler: the system’s failure? J Eur Acad Dermatol Venereol, 2013. 27(1): p. 121-3.
  5. Rose, A.E. and D. Day, Esthetic rejuvenation of the temple. Clin Plast Surg, 2013. 40(1): p. 77-89.
  6. Pontius, A.T., S.R. Chaiet, and E.F. Williams, 3rd, Midface injectable fillers: have they replaced midface surgery? Facial Plast Surg Clin North Am, 2013. 21(2): p. 229-39.
  7. Kontis, T.C., Contemporary review of injectable facial fillers. JAMA Facial Plast Surg, 2013. 15(1): p. 58-64.
  8. Duracinsky, M., et al., A longitudinal evaluation of the impact of a polylactic acid injection therapy on health related quality of life amongst HIV patients treated with anti-retroviral agents under real conditions of use. BMC Infect Dis, 2013. 13: p. 92.
  9. Binder, W.J., K. Dhir, and J. Joseph, The role of fillers in facial implant surgery. Facial Plast Surg Clin North Am, 2013. 21(2): p. 201-11.
  10. Roberts, S.A. and B.P. Arthurs, Severe visual loss and orbital infarction following periorbital aesthetic poly-(L)-lactic acid (PLLA) injection. Ophthal Plast Reconstr Surg, 2012. 28(3): p. e68-70.
  11. Palm, M. and P. Chayavichitsilp, The “skinny”on Sculptra: a practical primer to volumization with poly-L-lactic acid. J Drugs Dermatol, 2012. 11(9): p. 1046-52.
  12. Nguyen, A.T., et al., Cosmetic medicine: facial resurfacing and injectables. Plast Reconstr Surg, 2012. 129(1): p. 142e-153e.
  13. Nelson, L. and K.J. Stewart, Psychological morbidity and facial volume in HIV lipodystrophy: quantification of treatment outcome. J Plast Reconstr Aesthet Surg, 2012. 65(4): p. 439-47.
  14. Guardiani, E. and S.P. Davison, Angioedema after treatment with injectable poly-L-lactic acid (sculptra). Plast Reconstr Surg, 2012. 129(1): p. 187e-189e.
  15. Glogau, R.G., Fillers: from the past to the future. Semin Cutan Med Surg, 2012. 31(2): p. 78-87.
  16. Dayan, S.H., D.A. Ellis, and M.L. Moran, Facial fillers: discussion and debate. Facial Plast Surg Clin North Am, 2012. 20(3): p. 245-64.
  17. Schierle, C.F. and L.A. Casas, Nonsurgical rejuvenation of the aging face with injectable poly-L-lactic acid for restoration of soft tissue volume. Aesthet Surg J, 2011. 31(1): p. 95-109.
  18. Olivier Masveyraud, F., [Facial rejuvenation using L-polylactic acid: about 298 successive cases]. Ann Chir Plast Esthet, 2011. 56(2): p. 120-7.
  19. Goldman, M.P., Cosmetic use of poly-L-lactic acid: my technique for success and minimizing complications. Dermatol Surg, 2011. 37(5): p. 688-93.
  20. Hamilton, T.K. and C.M. Burgess, Considerations for the use of injectable poly-L-lactic acid in people of color. J Drugs Dermatol, 2010. 9(5): p. 451-6.
  21. Sadick, N.S. and L. Palmisano, Case study involving use of injectable poly-L-lactic acid (PLLA) for acne scars. J Dermatolog Treat, 2009. 20(5): p. 302-7.
  22. Reszko, A.E., et al., Late-onset subcutaneous nodules after poly-L-lactic acid injection. Dermatol Surg, 2009. 35 Suppl 1: p. 380-4.
  23. Mest, D.R. and G.M. Humble, Duration of correction for human immunodeficiency virus-associated lipoatrophy after retreatment with injectable poly-L-lactic acid. Aesthetic Plast Surg, 2009. 33(4): p. 654-6.
  24. Lowe, N.J., et al., Injectable poly-l-lactic acid: 3 years of aesthetic experience. Dermatol Surg, 2009. 35 Suppl 1: p. 344-9.
  25. Lacombe, V., Sculptra: a stimulatory filler. Facial Plast Surg, 2009. 25(2): p. 95-9.
  26. Fitzgerald, R. and D. Vleggaar, Using poly-L-lactic acid (PLLA) to mimic volume in multiple tissue layers. J Drugs Dermatol, 2009. 8(10 Suppl): p. s5-14.
  27. Cobb, C., Saving face. Strategies to fight father time. Adv Nurse Pract, 2009. 17(4): p. 39-43, 68.
  28. Azizzadeh, B., Late-onset infections and granuloma formation after facial polylactic acid (new-fill) injections in women who are heavy smokers. Plast Reconstr Surg, 2009. 124(1): p. 316-7; author reply 317-8.
  29. Thiery, G., et al., [Poly-L-lactic-acid filling of facial lipoatrophy in HIV+ patients under tritherapy]. Rev Stomatol Chir Maxillofac, 2008. 109(2): p. 103-5.
  30. Schulman, M.R., J. Lipper, and R.A. Skolnik, Correction of chest wall deformity after implant-based breast reconstruction using poly-L-lactic acid (Sculptra). Breast J, 2008. 14(1): p. 92-6.
  31. Sarnoff, D.S., R. Saini, and R.H. Gotkin, Comparison of filling agents for lip augmentation. Aesthet Surg J, 2008. 28(5): p. 556-63.
  32. Salles, A.G., et al., Evaluation of the poly-L-lactic acid implant for treatment of the nasolabial fold: 3-year follow-up evaluation. Aesthetic Plast Surg, 2008. 32(5): p. 753-6.
  33. Narins, R.S., Minimizing adverse events associated with poly-L-lactic acid injection. Dermatol Surg, 2008. 34 Suppl 1: p. S100-4.
  34. Mole, B., [Long-lasting filling procedures]. Ann Dermatol Venereol, 2008. 135(1 Pt 2): p. 1S39-47.
  35. Lowe, N.J., Optimizing poly-L-lactic acid use. J Cosmet Laser Ther, 2008. 10(1): p. 43-6.
  36. Levy, R.M., K.P. Redbord, and C.W. Hanke, Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study. J Am Acad Dermatol, 2008. 59(6): p. 923-33.
  37. Hotta, T., Core curriculum for plastic surgical nursing: dermal fillers. Plast Surg Nurs, 2008. 28(3): p. 131-5.
  38. Hamilton, D.G., N. Gauthier, and B.F. Robertson, Late-onset, recurrent facial nodules associated with injection of poly-L-lactic acid. Dermatol Surg, 2008. 34(1): p. 123-6; discussion 126.
  39. Grimaldi, M., et al., Lipostructure technique in Romberg syndrome. J Craniofac Surg, 2008. 19(4): p. 1089-91.
  40. Goldan, O., et al., Late-onset infections and granuloma formation after facial polylactic acid (New-Fill) injections in women who are heavy smokers. Plast Reconstr Surg, 2008. 121(5): p. 336e-338e.
  41. Dinman, S., Sculptra use in HIV-associated lipodystrophy. Plast Surg Nurs, 2008. 28(1): p. 53-4.
  42. Busso, M., Soft tissue augmentation: nonsurgical approaches to treatment of the mid and lower facial regions. Dermatol Nurs, 2008. 20(3): p. 211-4, 217-9.
  43. Burgess, C.M., Treatment of facial asymmetry with poly-L-lactic Acid: a case study. Aesthetic Plast Surg, 2008. 32(3): p. 552-4.
  44. Stewart, D.B., et al., Management of visible granulomas following periorbital injection of poly-L-lactic Acid. Ophthal Plast Reconstr Surg, 2007. 23(4): p. 298-301.
  45. Piquet, M., et al., [Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy]. Rev Stomatol Chir Maxillofac, 2007. 108(6): p. 496-504.
  46. Keni, S.P. and D.M. Sidle, Sculptra (injectable poly-L-lactic acid). Facial Plast Surg Clin North Am, 2007. 15(1): p. 91-7, vii.
  47. Kelly, P.E., Injectable success: from fillers to Botox. Facial Plast Surg, 2007. 23(1): p. 7-18; discussion 19-20.
  48. Heffelfinger, R.N., et al., A simplified approach to midface aging. Arch Facial Plast Surg, 2007. 9(1): p. 48-55.
  49. Davison, S.P., J. Timpone, Jr., and C.M. Hannan, Surgical algorithm for management of HIV lipodystrophy. Plast Reconstr Surg, 2007. 120(7): p. 1843-58.
  50. Clymer, M.A., Evolution in techniques: lip augmentation. Facial Plast Surg, 2007. 23(1): p. 21-6.
  51. Beer, K., A single-center, open-label study on the use of injectable poly-L-lactic acid for the treatment of moderate to severe scarring from acne or varicella. Dermatol Surg, 2007. 33 Suppl 2: p. S159-67.
  52. Apikian, M., S. Roberts, and G.J. Goodman, Adverse reactions to polylactic acid injections in the periorbital area. J Cosmet Dermatol, 2007. 6(2): p. 95-101.
  53. Wolfram, D., A. Tzankov, and H. Piza-Katzer, Surgery for foreign body reactions due to injectable fillers. Dermatology, 2006. 213(4): p. 300-4.
  54. Vleggaar, D., Poly-L-lactic acid: consultation on the injection techniques. J Eur Acad Dermatol Venereol, 2006. 20 Suppl 1: p. 17-21.
  55. Thioly-Bensoussan, D., A new option for volumetric restoration: poly-L-lactic acid. J Eur Acad Dermatol Venereol, 2006. 20 Suppl 1: p. 12-6.
  56. Shumaker, P.R., et al., Effect of monopolar radiofrequency treatment over soft-tissue fillers in an animal model: part 2. Lasers Surg Med, 2006. 38(3): p. 211-7.
  57. Sherman, R.N., Sculptra: the new three-dimensional filler. Clin Plast Surg, 2006. 33(4): p. 539-50.
  58. Ralston, J.P., J.E. Blume, and N.C. Zeitouni, Treatment of postoperative soft tissue loss with injectable poly-L-lactic acid. J Drugs Dermatol, 2006. 5(10): p. 1000-1.
  59. Lowe, N.J., Dispelling the myth: appropriate use of poly-L-lactic acid and clinical considerations. J Eur Acad Dermatol Venereol, 2006. 20 Suppl 1: p. 2-6.
  60. Lam, S.M., B. Azizzadeh, and M. Graivier, Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring. Plast Reconstr Surg, 2006. 118(3 Suppl): p. 55S-63S.
  61. Jones, J.K., Patient safety considerations regarding dermal filler injections. Plast Surg Nurs, 2006. 26(3): p. 156-63.
  62. Graivier, M., Wire subcision for complete release of depressions, subdermal attachments, and scars. Aesthet Surg J, 2006. 26(4): p. 387-94.
  63. El-Beyrouty, C., et al., Poly-L-lactic acid for facial lipoatrophy in HIV. Ann Pharmacother, 2006. 40(9): p. 1602-6.
  64. Downie, J.B., Esthetic considerations for ethnic skin. Semin Cutan Med Surg, 2006. 25(3): p. 158-62.
  65. Broder, K.W. and S.R. Cohen, An overview of permanent and semipermanent fillers. Plast Reconstr Surg, 2006. 118(3 Suppl): p. 7S-14S.
  66. Beer, K.R. and M.I. Rendon, Use of sculptra mark in esthetic rejuvenation. Semin Cutan Med Surg, 2006. 25(3): p. 127-31.
  67. Bauer, U. and D. Vleggaar, Response to “New-fill injections may induce late-onset foreign body granulomatous reaction”. Plast Reconstr Surg, 2006. 118(1): p. 265; author reply 265-6.
  68. Vleggaar, D., Facial volumetric correction with injectable poly-L-lactic acid. Dermatol Surg, 2005. 31(11 Pt 2): p. 1511-7; discussion 1517-8.
  69. Parada, M.B., et al., A histologic study of adverse effects of different cosmetic skin fillers. Skinmed, 2005. 4(6): p. 345-9.
  70. Moy, R.L. and E.F. Fincher, Poly-L-lactic acid for the aesthetic correction of facial volume loss. Aesthet Surg J, 2005. 25(6): p. 646-8.
  71. Lowe, N.J., C.A. Maxwell, and R. Patnaik, Adverse reactions to dermal fillers: review. Dermatol Surg, 2005. 31(11 Pt 2): p. 1616-25.
  72. Jones, D., HIV facial lipoatrophy: causes and treatment options. Dermatol Surg, 2005. 31(11 Pt 2): p. 1519-29; discussion 1529.
  73. James, J.S., Sculptra facial treatment: new physician locator. AIDS Treat News, 2005(410): p. 4.
  74. Hamilton, M.M. and T. Hobgood, Emerging trends and techniques in male aesthetic surgery. Facial Plast Surg, 2005. 21(4): p. 324-8.
  75. England, L.J., et al., Effects of monopolar radiofrequency treatment over soft-tissue fillers in an animal model. Lasers Surg Med, 2005. 37(5): p. 356-65.
  76. Engelhard, P., G. Humble, and D. Mest, Safety of Sculptra: a review of clinical trial data. J Cosmet Laser Ther, 2005. 7(3-4): p. 201-5.
  77. Dijkema, S.J., B. van der Lei, and R.E. Kibbelaar, New-fill injections may induce late-onset foreign body granulomatous reaction. Plast Reconstr Surg, 2005. 115(5): p. 76e-78e.
  78. Christensen, L., et al., Adverse reactions to injectable soft tissue permanent fillers. Aesthetic Plast Surg, 2005. 29(1): p. 34-48.
  79. Burgess, C.M. and R.M. Quiroga, Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. J Am Acad Dermatol, 2005. 52(2): p. 233-9.
  80. Borelli, C., et al., Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients. Skin Pharmacol Physiol, 2005. 18(6): p. 273-8.
  81. Beljaards, R.C., K.P. de Roos, and F.G. Bruins, NewFill for skin augmentation: a new filler or failure? Dermatol Surg, 2005. 31(7 Pt 1): p. 772-6; discussion 776.
  82. Andre, P., et al., Adverse reactions to dermal fillers: a review of European experiences. J Cosmet Laser Ther, 2005. 7(3-4): p. 171-6.
  83. Zimmermann, U.S. and T.J. Clerici, The histological aspects of fillers complications. Semin Cutan Med Surg, 2004. 23(4): p. 241-50.
  84. Vochelle, D., The use of poly-L-lactic acid in the management of soft-tissue augmentation: a five-year experience. Semin Cutan Med Surg, 2004. 23(4): p. 223-6.
  85. Vleggaar, D. and U. Bauer, Facial enhancement and the European experience with Sculptra (poly-l-lactic acid). J Drugs Dermatol, 2004. 3(5): p. 542-7.
  86. Munk, B., Sculptra. Posit Aware, 2004. 15(6): p. 31-2.
  87. Moyle, G.J., et al., A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med, 2004. 5(2): p. 82-7.
  88. Lombardi, T., et al., Orofacial granulomas after injection of cosmetic fillers. Histopathologic and clinical study of 11 cases. J Oral Pathol Med, 2004. 33(2): p. 115-20.
  89. James, J.S., Sculptra (formerly New Fill) for facial wasting–where to find information on the patient-assistance program. AIDS Treat News, 2004(407-408): p. 5.
  90. Humble, G. and D. Mest, Soft tissue augmentation using sculptra. Facial Plast Surg, 2004. 20(2): p. 157-63.
  91. Huff, B., Approval of Sculptra recommended. GMHC Treat Issues, 2004. 18(3-4): p. 15.
  92. FDA approves lipoatrophy filler. AIDS Patient Care STDS, 2004. 18(6): p. 366.
  93. Valantin, M.A., et al., Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS, 2003. 17(17): p. 2471-7.
  94. Lemperle, G., V. Morhenn, and U. Charrier, Human histology and persistence of various injectable filler substances for soft tissue augmentation. Aesthetic Plast Surg, 2003. 27(5): p. 354-66; discussion 367.
  95. Cheonis, N., New-Fill to treat facial wasting. BETA, 2002. 15(2): p. 10-5.
  96. Berry, J., New-Fill for an old face. Posit Aware, 2002. 13(3): p. 34-5.
  97. Berger, D.S., New-Fill on “hold” and open-label for T-20. Posit Aware, 2002. 13(1): p. 64-5.

 

update: june 2015

 

NVCG congres 28 november 2020
PROGRAMMA